Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | C3AR1 | Q16581 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL517249 | 1.00 | TDP1 (0.42) | TDP1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL517076 | 0.99 | TDP1 (0.43) | TDP1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL517236 | 0.97 | TDP1 (0.43) | TDP1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL517789 | 0.92 | TP53 (0.44) | TDP1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL16457501 | 0.92 | TP53 (0.44) | TDP1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL517305 | 0.92 | TP53 (0.44) | TDP1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL518071 | 0.92 | TP53 (0.45) | TDP1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL517315 | 0.89 | TP53 (0.46) | TDP1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1725285 | 0.88 | TP53 (0.42) | TDP1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7907383 | 0.88 | TP53 (0.41) | TDP1TP53CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406215-B1 | OXO-HETEROCYCLICALLY SUBSTITUTED ALKYL CARBOXYLIC ACIDS AND USE THEREOF | BAYER IP GMBH (DE) | 2014-04-16 | — | — | EP | disclosed |
| EP-2406215-B1 | OXO-HETEROCYCLICALLY SUBSTITUTED ALKYL CARBOXYLIC ACIDS AND USE THEREOF | BAYER IP GMBH (DE) | 2014-04-16 | — | — | EP | disclosed |
| US-8642592-B2 | Oxo-heterocyclically substituted alkyl carboxylic acids and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-8642592-B2 | Oxo-heterocyclically substituted alkyl carboxylic acids and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-8642592-B2 | Oxo-heterocyclically substituted alkyl carboxylic acids and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-20120028971-A1 | OXO-HETEROCYCLICALLY SUBSTITUTED ALKYL CARBOXYLIC ACIDS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028971-A1 | OXO-HETEROCYCLICALLY SUBSTITUTED ALKYL CARBOXYLIC ACIDS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028971-A1 | OXO-HETEROCYCLICALLY SUBSTITUTED ALKYL CARBOXYLIC ACIDS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-02 | — | — | US | disclosed |
| EP-2406215-A1 | OXO-HETEROCYCLICALLY SUBSTITUTED ALKYL CARBOXYLIC ACIDS AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010102717-A1 | OXO-HETEROCYCLICALLY SUBSTITUTED ALKYL CARBOXYLIC ACIDS AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010102717-A1 | OXO-HETEROCYCLICALLY SUBSTITUTED ALKYL CARBOXYLIC ACIDS AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028971-A1 | OXO-HETEROCYCLICALLY SUBSTITUTED ALKYL CARBOXYLIC ACIDS AND USE THEREOF | AADAC, OTC, HCAR2 | TDP1 2877/4885TP53 2138/4885CYP1A2 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.